Compare prices and buy Semaglutide + Cagrilintide Blend from 10 research peptide vendors - also called suppliers or sources. Updated daily.
A research blend of the GLP-1 receptor agonist semaglutide and the amylin analog cagrilintide in one vial. Novo Nordisk pairs the same two molecules in CagriSema, its fixed-dose combination tested in Phase 3 trials in obesity and type 2 diabetes. A vendor blend is a market convention and is not CagriSema, and its listed size is the total of both components.
For research purposes only. Not medical advice.
The semaglutide + cagrilintide blend puts two Novo Nordisk peptides in one vial. Semaglutide is a GLP-1 receptor agonist, and cagrilintide is a long-acting analog of the pancreatic hormone amylin. Each has its own page for structure, mechanism and regulatory status. Novo Nordisk describes the pairing as targeting complementary obesity-related pathways, and the cagrilintide page sets out why amylin and GLP-1 signaling are counted as separate mechanisms.
The blend is a mixture, so it has no CAS number of its own. In-stock listings that state a split in October 2026 give equal parts of each peptide by mass.
The retatrutide + cagrilintide blend has no clinical trial counterpart. This one does. Novo Nordisk's CagriSema combines the same two peptides, and its Phase 3 REDEFINE program tested the combination in people.
REDEFINE 1 (Garvey and colleagues, The New England Journal of Medicine, 2025) randomized adults with obesity, or with overweight and a related condition, who did not have diabetes. Participants received the combination, semaglutide alone, cagrilintide alone or placebo, so the trial measured the pair against each of its components. REDEFINE 2 (Davies and colleagues, same journal and year) enrolled adults with type 2 diabetes and overweight or obesity, and a separate program, REIMAGINE, studies the combination as a treatment for type 2 diabetes. The cagrilintide page carries the results of these trials, including the head-to-head comparison with tirzepatide.
The overlap is the two molecules. The receptor pharmacology on each component's page belongs to the molecule, so it applies to any vial that actually holds semaglutide and cagrilintide, and only a certificate of analysis that identifies and quantifies each peptide shows that one does. The rest of the trial record belongs to Novo Nordisk's product.
No efficacy or synergy claim for a research vial follows from the CagriSema trials. The semaglutide page also covers the FDA's position on semaglutide salt forms.
Each component has its own regulatory story. Semaglutide is the active ingredient in Novo Nordisk's FDA-approved Ozempic, Rybelsus and Wegovy, and those approvals, rather than the bulk-substance nomination lists that govern older research peptides, set its status. Cagrilintide holds no FDA approval and remains investigational, and its page covers why it is not eligible for compounding.
Novo Nordisk submitted a New Drug Application for CagriSema to the FDA on December 18, 2025, for reducing excess body weight and maintaining the reduction in adults with obesity, or with overweight and at least one weight-related condition. As of October 21, 2026, Drugs@FDA lists no approval for CagriSema or for any product containing cagrilintide, and every semaglutide product it lists has semaglutide as its only active ingredient. No approved product combines the two.
Vendor titles join a name or code for each component.
PeptideScouter records a blend's size as the vial's total peptide content, and the blend is sold as vials, so its listings carry a per-milligram price. With equal parts neither peptide dominates the mass, and the figure compares only with an equal-weighted average of the two single-compound prices. A listing that does not state its split cannot be placed against that average. The retatrutide + cagrilintide page explains how blend sizes and prices are recorded.
Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
No. CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide and semaglutide, developed for a dual-chamber prefilled pen and submitted to the FDA in a New Drug Application in December 2025. A vendor blend puts the same two peptides, by name, in one research vial, with a split and preparation chosen by the vendor. Only a certificate of analysis that identifies and quantifies each peptide shows what a vial holds. Material sold by research peptide vendors is offered for laboratory research use only and not for human consumption.
No. The REDEFINE trials, published in The New England Journal of Medicine in 2025, tested Novo Nordisk's product in trial participants, and REDEFINE 1 compared it with semaglutide alone, cagrilintide alone and placebo. Those results describe that product given under each trial's protocol. They are not evidence about the contents or effects of a vial sold by a research peptide vendor.
Not as of October 21, 2026. Novo Nordisk submitted a New Drug Application for CagriSema on December 18, 2025, for weight management in adults with obesity, or with overweight and at least one weight-related condition, and Drugs@FDA lists no approval for it or for any product containing cagrilintide. Semaglutide by itself is FDA-approved in Novo Nordisk's Ozempic, Rybelsus and Wegovy, while cagrilintide by itself is investigational. An approval of CagriSema would cover Novo Nordisk's product as filed, not research-grade blends.
CagriSema combines equal amounts of the two peptides. In October 2026, in-stock vendor listings that state a split also give equal parts by mass. PeptideScouter records the combined total as the vial size, so with an equal split each peptide makes up half the listed size. A stated split is the vendor's label claim, and only a certificate of analysis that quantifies each peptide confirms it.
Semaglutide + Cagrilintide Blend is sold by 10 research peptide vendors indexed on PeptideScouter, with 13 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
9 of the 10 indexed vendors currently have Semaglutide + Cagrilintide Blend in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Studz Peptides currently lists Semaglutide + Cagrilintide Blend at $3.00/mg, the lowest listed price across 10 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.70/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 10 vendors listing Semaglutide + Cagrilintide Blend publish a PeptideScouter code, worth 10% to 20% off. Applied, the lowest effective price falls from $3.00/mg listed to $2.70/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
Semaglutide + Cagrilintide Blend ranges from $3.00/mg to $18.00/mg across 13 listings from 10 research peptide vendors, normalized to USD per milligram and refreshed daily.
10 research peptide vendors currently list Semaglutide + Cagrilintide Blend on PeptideScouter, with 9 in stock right now. We track 13 listings across size and kit variants.
